In recent years, inhibitors targeting key signaling pathways, such as AKT, MAPK/ERK, and STAT3, have gained prominence in cancer therapy due to their critical roles in the regulation of tumor growth, survival, and metastasis, thereby making them prime targets for therapeutic intervention [55]. This evidence concerns the gene AKT1 and neoplasm.